ArticlePediatric nephrology (Berlin, Germany)2025
The incidence of acute kidney injury in very-low-birth-weight infants treated early with caffeine.
Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk of acute kidney injury following intravenous iodinated contrast exposure among pediatric population: a narrative review.Pediatric radiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcute kidney injury (AKI) in neonates is associated with increased morbidity and mortality, longer hospitalization, and a higher risk for future kidney damage. Caffeine treatment has reportedly been associated with a decreased AKI occurrence. However, previous studies lack uniformity regarding dosage and timing of administration. This study aimed to assess AKI incidence in very-low-birth-weight (VLBW) preterm infants (< 1500 g) treated with early high-dose caffeine and to identify risk factors associated with AKI.
methodsA retrospective cohort study of VLBW preterm infants admitted to the Neonatal Intensive Care Unit at the Shaare Zedek Medical Center between January 1, 2017, and December 31, 2019. All VLBW infants born < 32 weeks of gestation were treated with a standardized caffeine regimen (20 mg/kg bolus; in the first hour of life, maintenance 10 mg/kg/day). Maternal and infant data including clinical, demographic, and laboratory measurements were retrieved from electronic medical records.
resultsOf 311 VLBW infants admitted, all had adequate serum creatinine and urine output data. Of 301 patients included for analysis, 41 (14%) were diagnosed with AKI, while only 12/301 (4%) were diagnosed during the first week of life. Sixteen infants (5%) had > 1 AKI episode. Seven (7/41, 17%) had AKI stage 1 and seventeen infants (17/41, 42%) had stages 2 and 3. In univariate analysis, sepsis, patent ductus arteriosus, necrotizing enterocolitis (NEC), and hemodynamic instability during the first week of life were more prevalent in the AKI group. Infants with AKI were born with lower birth weights, at earlier gestational weeks, and had lower APGAR and higher CRIB II scores. NEC was the only significant risk factor associated with AKI in multivariate analysis. They also had a higher risk for bronchopulmonary dysplasia (BPD), longer hospitalization, and higher mortality rate.
conclusionsThe incidence of AKI in a cohort of VLBW infants universally treated early with caffeine was 14%, while only 4% had AKI during the first week. Infants with AKI had worse outcomes (BPD and mortality) and longer hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.